Eribulin mesylate exerts antitumor effects via CD103
Eribulin mesylate (ERB) is a synthetic analog of halichondrin B, inhibiting tumor cell growth by disrupting microtubule function. Recently, anticancer drugs have been shown to not only act directly on tumor cells but also to exert antitumor effects by modifying the tumor environment. Although ERB ha...
Saved in:
| Main Authors: | Kazumasa Oya, Yoshiyuki Nakamura, Rei Watanabe, Ryota Tanaka, Yuki Ichimura, Noriko Kubota, Yutaka Matsumura, Hideaki Tahara, Naoko Okiyama, Manabu Fujimoto, Toshifumi Nomura, Yasuhiro Fujisawa |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Taylor & Francis Group
2023-12-01
|
| Series: | OncoImmunology |
| Subjects: | |
| Online Access: | https://www.tandfonline.com/doi/10.1080/2162402X.2023.2218782 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Efficacy and safety of eribulin mesylate in advanced soft tissue sarcomas
by: Jonathan Noujaim, et al.
Published: (2016-01-01) -
Cost-effectiveness analysis of eribulin versus dacarbazine in patients with advanced liposarcoma
by: Miaomiao Zhang, et al.
Published: (2025-01-01) -
CLINICAL ECONOMIC ANALYSIS OF USING ERIBULIN (HALAVEN®) FOR TREATMENT OF PATIENTS WITH METASTATIC BREAST CANCER
by: S. L. Plavinsky, et al.
Published: (2016-02-01) -
Microenvironment-related predictive markers of the therapeutic effectiveness of eribulin in patients with locally advanced or metastatic breast cancer: pilot study
by: L. A. Tashireva, et al.
Published: (2022-01-01) -
Eribulin in Heavily Pre-Treated Metastatic Breast Cancer: A Case Series
by: Andini Kartikasari, et al.
Published: (2025-04-01)